跳至主要内容
临床试验/NCT02514200
NCT02514200Unknown2 期

Treatment of Keratoconus With Advanced Corneal Crosslinking-II

Umeå University0 个研究点目标入组 50 人开始时间: 2014年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
入组人数
50
主要终点
Change from baseline in refraction

研究概览

简要总结

The purpose of this study is to determine whether individualized, topography-based corneal crosslinking for keratoconus can improve the optical outcomes of the treatment.

详细描述

The study is designed as a prospective, open label, randomized controlled trial involving patients aged 12 years or older of both genders with uni- or bilateral keratoconus planned for routine corneal crosslinking (CXL) at the Department of Clinical Sciences / Ophthalmology, Umeå University Hospital, Umeå, Sweden. The study involves 25+25 eyes with keratoconus, which are randomized to receive either conventional pulsed crosslinking with a uniform, universal 8 mm treatment pattern of 5.4 J/cm2 (pCXL; n=25), or a modified treatment - individualized topography-based corneal crosslinking (KXL2; n=25). In the latter treatment zone has an individualized arcuate shape and spares a 2 mm central optical zone. The size of the treatment zone is based on Pentacam HR® corneal tomography, and is determined by the transition zone where the corneal curvature drops off by ≥2D. The energy distribution is based on the maximum corneal steepness (Kmax) value retrieved from the Pentacam HR® tomography: ≤47.0D - 7.2 J/cm2; 47.1-52.0D - 10 J/cm2; ≥52.1D - 15 J/cm2. Thus, the thin protruding areas of the cornea are crosslinked, whereas the parts with a more normal shape are not. The aim is to potentially improve the optical outcome after the treatment.

Patients are randomized to either of the two treatment arms utilizing a computer list of unique random numbers between 1 and 50; an even number will be treated with KXL2 and an uneven number with pCXL. Bilateral inclusion is allowed, and the second eye to be treated will be assigned to the other group, i.e. eye number two will not get the same treatment as eye number 1.

All patients are informed about the procedures and provide oral and written consent before inclusion in the study.

At baseline, before treatment, each eye is evaluated with autorefractometer measurement (Oculus Parc-1®), uncorrected and best spectacle-corrected LogMAR visual acuity, Oculus Pentacam HR® Scheimpflug photography, Oculus CorVis® high-speed Scheimpflug photography, corneal endothelial photography with a specular microscope camera, Goldmann applanation tonometry and biomicroscopy.

For the Pentacam HR® rotating Scheimpflug camera, each eye is photographed using the "25 pictures" program under standardized, mesopic light conditions. Multiple variables will be analyzed, and individual photographs also will be analyzed manually for light backscatter and for the occurrence of a demarcation line, by a masked observer. The corneal biomechanical characteristics are assessed with data from the Oculus CorVis®, and corneal endothelial morphometry, including endothelial cell density is assessed manually and automatically from specular microscopy photographs taken with the Topcon SP-2000 endothelial camera. All investigations are repeated at 1 month, 3 months, 6 months and 12 months after the treatment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients planned for corneal crosslinking.
  • Uni-or bilateral keratoconus diagnosis based on the Amsler-Krumeich grading and the "Total Deviation" keratoconus quantification value from the "Belin-Ambrosio enhanced ectasia" measurements of the Pentacam HR® Scheimpflug camera, and an altered red reflex and/or an irregular cornea seen as distortion of the keratometric mires.
  • Progression of the keratoconus in the eye in question, documented with Scheimpflug photography using the Oculus Pentacam HR® Scheimpflug camera and/or repeated subjective refraction and keratometry.
  • Minimum corneal thickness of 400 μm at the thinnest point after epithelial removal.
  • ≥12 years of age
  • No ocular abnormalities except keratoconus
  • No previous ocular surgery
  • No cognitive insufficiency interfering with the informed consent.

排除标准

  • Age under 12
  • Any corneal abnormalities except keratoconus
  • Previous ocular surgery
  • Cognitive insufficiency

研究组 & 干预措施

Topography-based CXL (KXL2)

Experimental

Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.

干预措施: Topography-based CXL (KXL2) (Procedure)

Topography-based CXL (KXL2)

Experimental

Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.

干预措施: Riboflavin (Drug)

Topography-based CXL (KXL2)

Experimental

Individualized pulsed topography-based corneal crosslinking; 1 second on, 1 second off; 7.2J/cm2 - 15.0J/cm2; arcuate treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.

干预措施: Avedro KXL II (Device)

Conventional pulsed CXL (pCXL)

Active Comparator

Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.

干预措施: Conventional pulsed CXL (pCXL) (Procedure)

Conventional pulsed CXL (pCXL)

Active Comparator

Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.

干预措施: Riboflavin (Drug)

Conventional pulsed CXL (pCXL)

Active Comparator

Conventional pulsed corneal crosslinking; 1 second on, 1 second off; 5.4 J/cm2; 8 mm central treatment zone. The Avedro KXL II™ System is used for the crosslinking after epithelial debridement in topical anesthesia and application of topical riboflavin every 3 minutes for 10 minutes.

干预措施: Avedro KXL II (Device)

结局指标

主要结局

Change from baseline in refraction

时间窗: 1, 3, 6 and 12 months after the treatment

Change from baseline in refractive errors, including lower and higher order aberrations in the cornea.

次要结局

  • Change from baseline in corneal endothelial morphometry(1, 3, 6 and 12 months after the treatment)
  • Change from baseline in ETDRS LogMAR visual acuity(1, 3, 6 and 12 months after the treatment)
  • Change from baseline in corneal densitometry(1, 3, 6 and 12 months after the treatment)
  • Change from baseline in corneal biomechanical stability measured with GAT(1, 3, 6 and 12 months after the treatment)
  • Change from baseline in corneal biomechanical stability measured with CorVis®(1, 3, 6 and 12 months after the treatment)

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Treatment of Keratoconus With Advanced CXL-II | 临床试验